PUBLISHER: The Business Research Company | PRODUCT CODE: 1662938
PUBLISHER: The Business Research Company | PRODUCT CODE: 1662938
Circulating tumor cells (CTCs) represent solid tumor-derived cells that have detached from the primary tumor and entered the bloodstream, providing valuable diagnostic and prognostic information for cancer.
The primary products related to circulating tumor cells encompass kits and reagents, along with blood collection tubes and devices or systems. Kits and reagents constitute a comprehensive set of consumables comprising elements such as a blood specimen separator, proprietary microfluidic capture chip, CTC enrichment, and immunostaining reagents. These products are utilized for collecting various specimens from the human body, including blood, bone marrow, and other bodily fluids. They leverage different technologies such as CTC enrichment, detection, and analysis, facilitating applications in clinical or liquid biopsy procedures, as well as in research endeavors.
The circulating tumor cells market research report is one of a series of new reports from The Business Research Company that provides circulating tumor cells market statistics, including circulating tumor cells industry global market size, regional shares, competitors with a circulating tumor cells market share, detailed circulating tumor cells market segments, market trends and opportunities, and any further data you may need to thrive in the circulating tumor cells industry. This circulating tumor cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The circulating tumor cells market size has grown rapidly in recent years. It will grow from $11.9 billion in 2024 to $13.37 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to cancer incidence and prevalence, clinical utility in cancer staging, emergence of liquid biopsy, patient demand for minimally invasive tests, regulatory support for liquid biopsies, focus on early cancer detection.
The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $21.68 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to point-of-care CTC testing, adoption of microfluidics, focus on rare cancer types, standardization of CTC assays, expansion of CTC-based clinical trials, economic and emerging market growth. Major trends in the forecast period include innovations in CTC isolation techniques, government funding for CTC research, advancements in CTC detection technologies, liquid biopsy for cancer monitoring, integration with single-cell analysis, technological convergence with artificial intelligence (AI).
The increasing incidence of cancer is expected to drive the growth of the circulating tumor cells market in the future. Cancer is a disease characterized by the uncontrolled growth of certain body cells, which can spread to other areas. Circulating tumor cells are utilized for the early detection and diagnosis of cancer, thereby contributing to the expansion of the circulating tumor cells market as cancer cases rise. For example, in January 2023, the American Cancer Society Journals, a US-based voluntary health organization, projected that 1,958,310 new cancer cases would be diagnosed in the United States, with 609,820 expected cancer-related deaths. Thus, the rising incidence of cancer is fueling the growth of the circulating tumor cells market.
The increasing adoption of circulating tumor cells analysis in clinical trials is poised to be a significant driver for the market's growth. Clinical trials, essential for assessing the safety and efficacy of new medical treatments, benefit from the integration of circulating tumor cells (CTC) analysis. This integration enhances the ability to evaluate treatment response, enable early detection and monitoring, tailor interventions to specific patient profiles, and overall, improve the efficiency and validation of clinical endpoints. As of May 2023, ClinicalTrials.gov reported 452,604 registered clinical studies, with 64,838 actively seeking participants. This surge in clinical trials, up from 365,000 registered trials in 2021, underscores the increasing adoption of circulating tumor cells analysis in research. Consequently, the growing integration of CTC analysis in clinical trials is a key driver propelling the circulating tumor cells market.
Product innovations are a significant trend gaining traction in the circulating tumor cells market. Major companies in this sector are concentrating on developing innovative products to bolster their market position. For example, in June 2024, Bio-Rad Laboratories, Inc., a US-based medical laboratory, introduced the Celselect Slides 2.0. This product is designed to improve the capture of rare cells and circulating tumor cells (CTCs), thereby enhancing the accuracy and efficiency of cell analysis for both clinical and research applications.
Major players in the circulating tumor cells market are strategically focusing on the development of innovative products, particularly in the domain of oncology liquid biopsy, to drive revenue growth. Oncology liquid biopsy involves a minimally invasive or non-invasive technique for detecting and monitoring disease biomarkers present in bodily fluids such as blood, urine, and sputum. A case in point is BillionToOne Inc., a prominent US-based biotech company specializing in molecular diagnostics. In June 2022, the company introduced oncology liquid biopsy products, namely NorthStar Select and NorthStar Response. NorthStar Select is a comprehensive somatic mutation profiling panel designed for cancer, utilizing BillionToOne's unique molecular counting method, Quantitative Counting Templates (QCTs), to identify actionable mutations with a notable limit of detection. On the other hand, NorthStar Response is a tissue-neutral, methylation-based treatment response monitoring test, providing precise estimates of circulating tumor DNA (ctDNA) methylation burden through molecular counting technologies.
In August 2023, Cell Microsystems, a US-based biotechnology company, acquired Fluxion Biosciences for an undisclosed amount. This acquisition is intended to strengthen Cell Microsystems' capabilities in cell analysis and offer advanced solutions for both research and clinical applications. Fluxion Biosciences, also based in the US, specializes in technologies for isolating and analyzing circulating tumor cells (CTCs).
Major companies operating in the circulating tumor cells market include Precision Medicine Group LLC, Bio-Techne Corporation, BIOCEPT Inc., Creativ MicroTech Inc., Fluxion Biosciences Inc., Ikonisys Inc., Qiagen N.V., ScreenCell SAS, STEMCELL Technologies Inc., Sysmex Corporation, Aviva Biosciences Corporation, LungLife AI Inc., Miltenyi Biotec GmbH, Menarini Silicon Biosystems S.p.A., Canopus Bioscience Ltd., IVDiagnostics Inc., BioFluidica Inc., Biolidics Limited, Rarecells Diagnostics SAS, LineaRx Inc., Thermo Fisher Scientific Inc., Greiner Bio-One International GmbH, Stanford Research Institute International, Agilent Technologies Inc., Resolution Bioscience Inc., Cynvenio Biosystems Inc., ApoCell Inc., Clearbridge BioMedics Pte. Ltd., Celsee Inc., RareCyte Inc., On-chip Biotechnologies Co. Ltd.
North America was the largest region in the circulating tumor cells market in 2024. Asia-Pacific is expected to be the fastest-growing region in the circulating tumor cells market during the forecast period. The regions covered in the circulating tumor cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the circulating tumor cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The circulating tumor cells market consists of sales of clinical samples, KRT7, PSMA positive cells, and TTF-1 positive. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Circulating Tumor Cells Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on circulating tumor cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for circulating tumor cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The circulating tumor cells market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.